Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms

References

• Barbaglia G, Macia F, Comas M, . Trends in hormone therapy use before and after publication of the Women’s Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061–4
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–5
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; CD002978
   PubMedGoogle Scholar
• Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009; CD004143
   PubMed Web of Science ®Google Scholar
• Prentice RL, Manson JE, Langer RD, . Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12–23
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2009
   Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S, Study 315 investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77–87
   PubMed Web of Science ®Google Scholar
• Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1–172.e10
   PubMed Web of Science ®Google Scholar
• Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1–238.e10
   PubMed Web of Science ®Google Scholar
• Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50:222–30
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16–23
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, . Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal Women. European Medicines Agency, 1–11. 10-13-2005
   Google Scholar
• Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry – Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommendations for Clinical Evaluation, 2003
   Google Scholar
• McNair DM, Lorr M, Droppleman LF. POMS Manual Profile of Mood States. San Diego: EdITS/Educational and Industrial Testing Service. 1–2, 1992:1–40
   Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25–31
   PubMed Web of Science ®Google Scholar
• Baracat EC, Barbosa IC, Giordano MG, . A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002; 5:60–9
   PubMed Web of Science ®Google Scholar
• Mendoza N, Pison JA, Fernandez M, . Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289–98
   PubMed Web of Science ®Google Scholar
• Nelson HD, Haney E, Humphrey L, . Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) 2005;120:1–6
   PubMedGoogle Scholar
• Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287: 622–7
   PubMed Web of Science ®Google Scholar
• Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 2006;166:155–60
   PubMed Web of Science ®Google Scholar
• Klosterhalfen S, Kellermann S, Braun S, . Gender and the nocebo response following conditioning and expectancy. J Psychosom Res 2009;66:323–8
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197–214
   PubMed Web of Science ®Google Scholar
• Biglia N, Sgandurra P, Peano E, . Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric 2009;12:310–18
   PubMed Web of Science ®Google Scholar
• Geller SE, Shulman LP, van Breemen RB, . Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009; 16:1156–66
   PubMed Web of Science ®Google Scholar
• Garcia JT, Gonzaga F, Tan D, . Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. Menopause 2010;17:303–8
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez EA, . Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20: 1578–83
   PubMed Web of Science ®Google Scholar